Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRad-Br phase II study of radiotherapy with atezolizumab + nab-paclitaxel in PD-L1-positive triple-negative breast cancer
jRCTs021210010Phase 2Active, not recruiting
- Start
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and paclitaxel in triple-negative breast cancer (TNBC), sponsored by none. Primary endpoints: Incidence rate of pre-specified adverse events of interest and Pre-specified adverse events of interest list. Started Apr 2022; status: active, not recruiting.
02
Drugs
atezolizumabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCTs021210010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210010.